WeatherStorm Forensic Accounting Long Short ETF
News
First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
Globe Newswire Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total...\n more…
FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
Globe Newswire NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (FLAG) today announced that it reconvened and then further adjourned, without conducting any other business, its virtual Special Meeting of Stockholders to August 28, 2023 at 10:30 a.m., Eastern time (the ...\n more…
Flag Stockholders: Reminder to Vote for Proposed Business Combination
Globe Newswire RESTON, Va, Aug. 16, 2023 (GLOBE NEWSWIRE) -- irst Light Acquisition Group, Inc. (FLAG) (NYSE American: FLAG), a special purpose acquisition company, reminds FLAG stockholders that the FLAG Board of Directors unanimously recommends that FLAG stockholders vote FOR the proposed business combination (...\n more…
First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
Globe Newswire RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (FLAG) (NYSE American: FLAG), a special purpose acquisition company, today announced that the U.S. Securities and Exchange Commission (the SEC) has declared effective FLAGs registration statement on Form S-4 (as ...\n more…
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Globe Newswire Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics, and supported by the First Light Acquisition Group Sponsors through the contribution of sponsor ...\n more…